ConductScience.org, home
ductal breast carcinoma in situ
API referenceFor AI assistants

Disease · MONDO_0005023

Comparisons in its trials26

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

1 to 20 of 26

Download this page as JSON
ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Arm I (Chemotherapy) vs Arm II (Chemotherapy, Trastuzumab): deaths from any cause48 of 1,62261 of 1,6283,250NCT01275677Trial comparisons
Arm I (Chemotherapy) vs Arm II (Chemotherapy, Trastuzumab): serious adverse events31 of 1,61596 of 1,6253,240NCT01275677Trial comparisons
Anastrozole vs Tamoxifen: Number of Breast Cancer Deaths3 of 1,4493 of 1,4892,938NCT00072462Trial comparisons
Anastrozole vs Tamoxifen: Number of Participants With ER- Breast Cancer Recurrence24 of 1,44915 of 1,4892,938NCT00072462Trial comparisons
Anastrozole vs Tamoxifen: Number of Participants With Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral Tumours103 of 1,449120 of 1,4892,938NCT00072462Trial comparisons
Anastrozole vs Tamoxifen: Number of Participants With ER+ Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral Tumours58 of 1,44982 of 1,4892,938NCT00072462Trial comparisons
Anastrozole vs Tamoxifen: Number of Non-breast Cancer Deaths59 of 1,44965 of 1,4892,938NCT00072462Trial comparisons
Anastrozole vs Tamoxifen: deaths from any cause62 of 1,44969 of 1,4892,938NCT00072462Trial comparisons
Anastrozole vs Tamoxifen: serious adverse events333 of 1,449371 of 1,4892,938NCT00072462Trial comparisons
Standard WBI vs WBI, Trastuzumab: deaths from any cause11 of 1,00510 of 9931,998NCT00769379Trial comparisons
Standard WBI vs WBI, Trastuzumab: serious adverse events3 of 9989 of 9901,988NCT00769379Trial comparisons
Arm I (4-OHT Topical Gel, Placebo) vs Arm II (Placebo, Oral Tamoxifen): deaths from any cause0 of 470 of 53100NCT02993159Trial comparisons
Arm I (4-OHT Topical Gel, Placebo) vs Arm II (Placebo, Oral Tamoxifen): serious adverse events0 of 470 of 53100NCT02993159Trial comparisons
Treatment Gel + Oral Placebo vs Placebo Gel + Oral Treatment: serious adverse events0 of 120 of 1426NCT00952731Trial comparisons
Group A- Palbociclib Before Surgery vs Group B- No Pre-operative Treatment: Toxcity Based on CTCAE5 of 50 of 1217NCT03535506Trial comparisons
Group A- Palbociclib Before Surgery vs Group B- No Pre-operative Treatment: Feasibility: Recruitment Rates5 of 511 of 1217NCT03535506Trial comparisons
Group A- Palbociclib Before Surgery vs Group B- No Pre-operative Treatment: deaths from any cause0 of 50 of 1217NCT03535506Trial comparisons
Group A- Palbociclib Before Surgery vs Group B- No Pre-operative Treatment: serious adverse events0 of 50 of 1217NCT03535506Trial comparisons
Group A- Palbociclib Before Surgery vs Group B- No Pre-operative Treatment: Pathologic Changes0 of 40 of 1115NCT03535506Trial comparisons
GM-CSF vs NPS+GM-CSF: deaths from any cause0 of 40 of 913NCT02636582Trial comparisons

diseases-2026-09-18-0.1.0

Next page

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005023/comparisons

API referenceFor AI assistants